DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Information source: Massachusetts General Hospital
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension

Intervention: Etanercept (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Alexandra B Kimball, MD, MPH, Principal Investigator, Affiliation: Massachusetts General Hospital, Brigham & Women's Hospital

Overall contact:
Lynne M Hermosilla, Phone: 617 726-5066, Email: harvardskinstudies@partners.org

Summary

People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. People with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol.

Clinical Details

Official title: Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Determine the effect of TNF-alpha antagonism with Etanercept on CRP levels from baseline to 6 months of treatment in subjects with psoriasis and metabolic syndrome.

Secondary outcome:

Determine the effect of TNF-alpha antagonism with Etanercept in patients with psoriasis and metabolic syndrome on PASI scores and markers of cardiac risk including inflammatory cytokines, acute phase reactants, lipid parameters and glucose tolerance.

Determine the effect of 6 months of TNF-alpha antagonism with Etanercept on endothelial function by measurement of flow-mediated vasodilation.

Determine the safety and tolerability of Etanercept in patients with psoriasis and metabolic syndrome over a 6-month period.

Detailed description: People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. People with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol. Insulin resistance means that the body does not respond well to the insulin in your blood. Therefore, both blood levels of insulin and glucose (sugar) are high.

This causes inflammation (irritation) in the body. Inflammation can cause an unhealthy response in your body and blood vessels, and can lead to blockages in the heart and other vessels.

TNF-alpha is a substance made by fat and inflammatory cells that helps cause inflammatory reactions. TNF-alpha is thought to be important in causing psoriasis. The drug Etanercept blocks TNF-alpha's actions, and has been approved by the Food and Drug Administration (FDA) for the treatment of psoriasis. We think that Etanercept may also reduce the inflammation associated with metabolic syndrome and decrease the risk of heart disease. People in this study will receive either Etanercept or placebo (contains no active drug).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Age > 18

2. Subject willing and able to give informed consent.

3. Adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

4. PASI > 10 and BSA affected with psoriasis > 10.

5. Abdominal obesity defined by waist hip ratio > 0. 90 for men and > 0. 85 for women and BMI ³ 30 kg/m2

Exclusion Criteria:

- On insulin or other diabetes (anti-hyperglycemic) medication

- Congestive Heart Failure

- Heart Attack, Stroke or Transient Ischemic Attack in last 3 months

- Unstable angina

- Pulmonary disease requiring oxygen

- SLE, optic neuritis, transverse myelitis, epilepsy

- Positive PPD

- Scheduled for upcoming surgery

- Known immunosuppression (for example, HIV)

- Known autoimmune disease

- Hepatitis B or Hepatitis C

- Pregnant or nursing

- Renal insufficiency (Creatinine >1. 5)

- Latex allergy

- Use of live vaccination in past 90 days

- Organ transplantation

- History of severe infection

- History of malignancy (except cured non-melanoma skin cancer)

Locations and Contacts

Lynne M Hermosilla, Phone: 617 726-5066, Email: harvardskinstudies@partners.org

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Alexandra B Kimball, MD, MPH, Phone: 617-726-5066, Email: harvardskinstudies@partners.org
Alexandra B Kimball, MD, MPH, Principal Investigator
Maria B Alora-Palli, MD, Sub-Investigator
Additional Information

Click here for more information about this study: Effects of TNF-alpha Antagonism in Patients with the Metabolic Syndrome and Psoriasis

Starting date: May 2007
Last updated: December 17, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012